Japan's Akazawa Aims to Visit US Next Week for More Trade Talks
'I will continue working vigorously toward a mutually beneficial agreement that protects Japan's national interests,' Akazawa said on the sidelines of the World Expo in Osaka on Saturday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
FTSE 100 LIVE: Markets calm as EU readies plan for no-deal trade scenario with US
The FTSE 100 (^FTSE) and European stocks were tepid on Monday morning, making small moves as the EU prepares a plan for a potential no-deal scenario in trade negotiations with the US. Leaders are set to meet early this week, according to a Bloomberg report, in order to formulate a plan ahead of the 1 August deadline set by president Donald Trump. As it stands, the US plans to implement tariffs on EU imports at 10% or higher, with fewer exemptions than once offered on the table, according to Bloomberg. Medical supplies, aviation and manufacturing equipment are among the items being haggled over. Negotiations are set to continue over the next fortnight. In previous weeks, the EU prepared a list of items imported from the US that it was prepared to slap higher levies on in order to strengthen its stance, while the US sent a letter saying the bloc would face a 30% tariff after the 1 August deadline, among other stipulations. London's premier index rose around 0.1% in early such as Antofagasta (ANTO.L), Anglo American (AAL.L) and Glencore (GLEN.L) led the index higher. Over in Germany, the DAX (^GDAXI) was flat. The CAC 40 (^FCHI) in Paris fell below the flatline. The pan-European STOXX 600 (^STOXX) also lacked direction, hovering slightly higher. Here's the US stock futures chart US stock futures higher as earnings season continues Our US team writes: US stock futures rose early Monday morning, as markets entered a critical week defined by megacap earnings and continued risk around President Trump's looming tariffs. S&P 500 (ES=F) futures climbed 0.2%, contracts on the Nasdaq 100 (NQ=F) gained 0.3%, while Dow Jones Industrial Average futures (YM=F) inched up 0.1%, reflecting a cautious tone after last week's record-setting rally in growth names. The Nasdaq advanced 1.5% last week, while the S&P 500 added 0.6%. The Dow lagged, finishing slightly negative. Investor focus is dominated by two topics for the upcoming week: policy clarity on trade and earnings from tech heavyweights. On Sunday, Commerce Secretary Howard Lutnick reaffirmed the White House's August 1 deadline for new tariffs, calling it a "hard stop" for compliance — before saying that he's looking at continued conversation beyond that date. Read more on Yahoo Finance Average UK house price down £5,000 The average price of a UK property coming to the market in July dropped by 1.2% to £373,709 in the largest monthly price drop at this time of year recorded in over 20 years of data, as new sellers lower their price expectations, according to Rightmove (RMV.L). According to the property site, this month's price drop of £4,531 comes as sellers lower expectations to catch buyers' attention amid a high supply of homes for sale. London, the country's largest regional market, leads the charge in price reductions with an overall drop of 1.5%, driven largely by Inner London, where prices fell by 2.1%. This market shift comes as sellers in the capital react to external factors, including changes to stamp duty and tax rules, while also trying to compete for the growing pool of potential buyers. Despite the price reductions, buyers are still active, with the number of sales agreed up 5% compared to this time last year. Furthermore, inquiries from potential buyers are 6% higher than in 2023, indicating continued demand. At the same time, affordability is improving for many buyers, helped by lower mortgage rates and rising wages. Read more on Yahoo Finance UK Good morning! Hello from London. Lucy Harley-McKeown here, gearing up to bring you the latest markets and economics headlines. This morning we have an update on UK house prices and also a trading statement from budget carrier Ryanair ( Trade tensions between the EU and US are also hotting up, so we'll be watching that, too. Let's get to it. Here's the US stock futures chart US stock futures higher as earnings season continues Our US team writes: US stock futures rose early Monday morning, as markets entered a critical week defined by megacap earnings and continued risk around President Trump's looming tariffs. S&P 500 (ES=F) futures climbed 0.2%, contracts on the Nasdaq 100 (NQ=F) gained 0.3%, while Dow Jones Industrial Average futures (YM=F) inched up 0.1%, reflecting a cautious tone after last week's record-setting rally in growth names. The Nasdaq advanced 1.5% last week, while the S&P 500 added 0.6%. The Dow lagged, finishing slightly negative. Investor focus is dominated by two topics for the upcoming week: policy clarity on trade and earnings from tech heavyweights. On Sunday, Commerce Secretary Howard Lutnick reaffirmed the White House's August 1 deadline for new tariffs, calling it a "hard stop" for compliance — before saying that he's looking at continued conversation beyond that date. Read more on Yahoo Finance Our US team writes: US stock futures rose early Monday morning, as markets entered a critical week defined by megacap earnings and continued risk around President Trump's looming tariffs. S&P 500 (ES=F) futures climbed 0.2%, contracts on the Nasdaq 100 (NQ=F) gained 0.3%, while Dow Jones Industrial Average futures (YM=F) inched up 0.1%, reflecting a cautious tone after last week's record-setting rally in growth names. The Nasdaq advanced 1.5% last week, while the S&P 500 added 0.6%. The Dow lagged, finishing slightly negative. Investor focus is dominated by two topics for the upcoming week: policy clarity on trade and earnings from tech heavyweights. On Sunday, Commerce Secretary Howard Lutnick reaffirmed the White House's August 1 deadline for new tariffs, calling it a "hard stop" for compliance — before saying that he's looking at continued conversation beyond that date. Read more on Yahoo Finance Average UK house price down £5,000 The average price of a UK property coming to the market in July dropped by 1.2% to £373,709 in the largest monthly price drop at this time of year recorded in over 20 years of data, as new sellers lower their price expectations, according to Rightmove (RMV.L). According to the property site, this month's price drop of £4,531 comes as sellers lower expectations to catch buyers' attention amid a high supply of homes for sale. London, the country's largest regional market, leads the charge in price reductions with an overall drop of 1.5%, driven largely by Inner London, where prices fell by 2.1%. This market shift comes as sellers in the capital react to external factors, including changes to stamp duty and tax rules, while also trying to compete for the growing pool of potential buyers. Despite the price reductions, buyers are still active, with the number of sales agreed up 5% compared to this time last year. Furthermore, inquiries from potential buyers are 6% higher than in 2023, indicating continued demand. At the same time, affordability is improving for many buyers, helped by lower mortgage rates and rising wages. Read more on Yahoo Finance UK The average price of a UK property coming to the market in July dropped by 1.2% to £373,709 in the largest monthly price drop at this time of year recorded in over 20 years of data, as new sellers lower their price expectations, according to Rightmove (RMV.L). According to the property site, this month's price drop of £4,531 comes as sellers lower expectations to catch buyers' attention amid a high supply of homes for sale. London, the country's largest regional market, leads the charge in price reductions with an overall drop of 1.5%, driven largely by Inner London, where prices fell by 2.1%. This market shift comes as sellers in the capital react to external factors, including changes to stamp duty and tax rules, while also trying to compete for the growing pool of potential buyers. Despite the price reductions, buyers are still active, with the number of sales agreed up 5% compared to this time last year. Furthermore, inquiries from potential buyers are 6% higher than in 2023, indicating continued demand. At the same time, affordability is improving for many buyers, helped by lower mortgage rates and rising wages. Read more on Yahoo Finance UK Good morning! Hello from London. Lucy Harley-McKeown here, gearing up to bring you the latest markets and economics headlines. This morning we have an update on UK house prices and also a trading statement from budget carrier Ryanair ( Trade tensions between the EU and US are also hotting up, so we'll be watching that, too. Let's get to it. Hello from London. Lucy Harley-McKeown here, gearing up to bring you the latest markets and economics headlines. This morning we have an update on UK house prices and also a trading statement from budget carrier Ryanair ( Trade tensions between the EU and US are also hotting up, so we'll be watching that, too. Let's get to it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Cell‑Based Assays Report 2025: Key Market Drivers, Tech Trends & Competitive Landscape to 2030
The global cell-based assays market is set to grow from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, marking a CAGR of 9.1%. This surge is fueled by the rising demand in drug discovery and increased R&D investments by the pharmaceutical and biotech industries. The prevalence of cancer is boosting the need for advanced therapies, while the growth of cell-based assays applications in chronic diseases and personalized medicine further propels market expansion. In 2024, the drug discovery and flow cytometry segments dominated the market. The US, with its strong healthcare infrastructure and biopharmaceutical industry, led the global market. Key companies in this sector include BD, Thermo Fisher Scientific, and Merck KGaA. Cell Based Assays Market Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030" has been added to global cell-based assays market is anticipated to expand from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.1%. This growth is fueled by escalating demand in drug discovery and the increasing need for sophisticated therapies, particularly in oncology. An uptick in research and development investments from pharmaceutical and biotechnology firms is another catalyst propelling market expansion. Drug Discovery's Dominance in Applications Within the applications segment, drug discovery is poised to retain its prominence through 2024. It encompasses subcategories such as toxicity, pharmacokinetics, and pharmacodynamics studies. The segment's ascendancy is largely attributed to the burgeoning incidence of cancer, which heightens demand for novel therapies. Additionally, robust investments and the emergence of contract research organizations are significantly advancing drug discovery efforts. Flow Cytometry Leads Technological Innovations In 2024, the flow cytometry segment emerged as a leader within the technology category, driven by its pivotal role in providing comprehensive cell-based assay measurements. Enhanced adoption of cutting-edge technologies for cell analysis continues to bolster this sector, ensuring its sustained growth trajectory. Regional Insights and U.S. Market Leadership The U.S. held a commanding position in the North American market in 2024, attributed to its stature as the largest biopharmaceutical hub globally. This leadership is strengthened by significant research investments and a robust healthcare framework. The emphasis on developing advanced cell-based therapies is a key driver in response to rising cancer cases. Notable Market Players: BD (US) Thermo Fisher Scientific Inc. (US) Danaher Corporation (US) Merck KGaA (Germany) Agilent Technologies, Inc. (US) Lonza (Switzerland) Charles River Laboratories (US) Bio-Rad Laboratories, Inc. (US) REVVITY (US) Sartorius AG (Germany) And others Research Coverage and Market Insights: The report categorizes the cell-based assays market based on offerings, technology, applications, end users, and regions. It elucidates major drivers, restraints, opportunities, and challenges influencing market dynamics. Additionally, a comprehensive analysis of key industry players, including product launches, collaborations, and acquisitions, sheds light on the competitive landscape. Key Insights for Stakeholders: Drivers such as increasing demand for drug discovery, rising prevalence of cancer, and heightened R&D investments. Constraints involving high costs and licensing restrictions. Opportunities in chronic diseases and personalized medicine sectors. Competitive assessment of major players highlighting their strategies and market positioning. Key Attributes: Report Attribute Details No. of Pages 449 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $17.84 Billion Forecasted Market Value (USD) by 2030 $27.55 Billion Compound Annual Growth Rate 9.1% Regions Covered Global Key Topics Covered: Market Dynamics Drivers Growing Demand For Drug Discovery & Development and Increasing Preference For Cell-Based Assays in Drug Discovery Government Support and Funding For Cell-Based Research Growing Efforts To Curtail Animal-Based Studies Rising Prevalence of Cancer Alliances To Accelerate Innovations in Drug Discovery Restraints High Cost of Instruments and Restrictions Imposed by Product End-User Licenses For Reagents Lack of Standardization of Protocols Used in Cell-Based Assays Opportunities Growing Applications of Cell-Based Assays in Chronic Diseases and Personalized Medicine Growth Opportunities in Emerging Economies Rising Adoption of AI in Drug Discovery and Cell Analysis Challenges Complexities in Assay Designs Shortage of Skilled Professionals Company Profiles Danaher Thermo Fisher Scientific Inc. Merck Kgaa BD Agilent Technologies, Inc. Lonza Eurofins Scientific Charles River Laboratories Bio-Rad Laboratories, Inc. Revvity Sartorius Ag Corning Incorporated Promega Corporation Cell Signaling Technology, Inc. Enzo Biochem Inc. Carna Biosciences, Inc. Intertek Group Plc Bico Cell Biolabs, Inc. Reaction Biology AAT Bioquest, Inc. Pestka Biomedical Laboratories, Inc. Neuromics BPS Bioscience, Inc. Bellbrook Labs Profacgen Bmg Labtech Gmbh Hanugen Therapeutics Altogen Labs Bioagilytix Labs For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Based Assays Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Trump Threatens Washington Commanders' RFK Stadium Deal Over Team Name
A Washington Commanders jersey displaying President Donald Trump's name sits in the Oval Office of the White House on May 5, 2025, as Trump announced Washington, D.C., would host the 2027 NFL Draft. Credit - Jim Lo Scalzo—EPA/Bloomberg/Getty Images 'Our country has far bigger problems! FOCUS on them, not nonsense,' Donald Trump tweeted in 2013. Then-President Barack Obama, Trump said, 'should not be telling' Washington, D.C.'s NFL team 'to change their name.' But now, there is a need to focus on the nonsense, it seems. As President Trump continues to try to turn attention away from scrutinizing his relationship with the late alleged sex trafficker Jeffrey Epstein, he posted twice on his Truth Social platform on Sunday about the name of the football franchise in the nation's capital as well as that of the MLB team in Cleveland, Ohio. 'The Washington 'Whatever's' should IMMEDIATELY change their name back to the Washington Redskins Football Team,' he posted. 'There is a big clamoring for this. Likewise, the Cleveland Indians, one of the six original baseball teams, with a storied past. Our great Indian people, in massive numbers, want this to happen. Their heritage and prestige is systematically being taken away from them. Times are different now than they were three or four years ago. We are a Country of passion and common sense. OWNERS, GET IT DONE!!!' In a follow-up, Trump added: 'I may put a restriction on them that if they don't change the name back to the original 'Washington Redskins,' and get rid of the ridiculous moniker, 'Washington Commanders,' I won't make a deal for them to build a Stadium in Washington. The Team would be much more valuable, and the Deal would be more exciting for everyone. Cleveland should do the same with the Cleveland Indians. The Owner of the Cleveland Baseball Team, Matt Dolan, who is very political, has lost three Elections in a row because of that ridiculous name change. What he doesn't understand is that if he changed the name back to the Cleveland Indians, he might actually win an Election. Indians are being treated very unfairly. MAKE INDIANS GREAT AGAIN (MIGA)!' (Dolan, a Republican who served five years in the Ohio House of Representatives and eight years in the state senate and whose father purchased the Cleveland baseball team in 2000, ran unsuccessfully for U.S. Senate in 2022 and 2024.) Amid widespread concern about social injustices across the U.S. in 2020, both the Washington Redskins and Cleveland Indians decided to change their controversial names out of respect for Native Americans. Washington became the Washington Football Team that year, and in 2022 adopted the name the Washington Commanders, while the Cleveland Indians transitioned to its current name, the Cleveland Guardians, in 2021. Read More: A Linguist's Analysis of the Redskins Defense Trump was never a fan of the name changes, tweeting in 2020: 'They name teams out of STRENGTH, not weakness, but now the Washington Redskins & Cleveland Indians, two fabled sports franchises, look like they are going to be changing their names in order to be politically correct. Indians, like Elizabeth Warren, must be very angry right now!' (Sen. Warren, a Massachusetts Democrat, has been mocked by Trump and other Republicans for her claims of Cherokee ancestry.) Trump's urging of the sports organizations to reverse their rebrandings comes as his second-term Administration has targeted diversity, equity, and inclusion initiatives in both the public and private sector. Speaking to reporters Sunday, Guardians' president of baseball operations Chris Antonetti said, 'We understand there are different perspectives on the decision we made a few years ago but obviously it's a decision we made. We've got the opportunity to build a brand as the Guardians over the last 4 years and are excited about the future.' The Commanders did not immediately issue a statement, but earlier this year, controlling owner Josh Harris said his team had no plans to change its name again. 'In this building, the name Commanders means something,' Harris said during a February press conference. 'It's about players who love football, are great at football, hit hard, mentally tough, great teammates.' It's unclear whether Trump has the authority to upend a deal that the Commanders and D.C. Mayor Muriel Bowser announced in April to return the team in 2030 to its former home at the capital's Robert F. Kennedy Memorial Stadium after having moved to Landover, Md., in 1997. Amid years of discussions about redeveloping the storied-but-defunct sports and events campus, Trump's predecessor, Joe Biden, signed into law in January a bill that transferred the land of the RFK Stadium from federal to local control for the next 99 years. Still, earlier this month, as some members of the D.C. Council expressed skepticism about the timeline and financing of the mayor's deal with the Commanders, Trump suggested he could intervene if the council doesn't approve it. 'It's a very important piece of property. It's a great piece of property,' Trump said, referring to the RFK Stadium site, 'You know, ultimately we control that. The federal government ultimately controls it, so we'll see what happens.' Contact us at letters@
